Shanghai First People's Hospital
Shanghai 201620
3 studies enrolling now · 12 studies all time
What they study most
Alzheimer Disease, Alzheimers Disease, Atopic Dermatitis, Branch Retinal Vein Occlusion, Breast Cancer, Central Retinal Vein Occlusion, Diabetic Macular Edema, Gastric Cancer, Hemiretinal Vein Occlusion, Macular Edema, Metastatic Breast Cancer, Uveitic Macular Edema
Studies at this site
- A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Recruiting now
- Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — Recruiting now
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Recruiting now
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer — Completed
- A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion — Completed
- A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion — Completed
- Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) — Stopped early
- A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer — Completed
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer — Stopped early